Talk:OncoMed

This article is rated Start-class on Wikipedia's content assessment scale.
It is of interest to the following WikiProjects:

Companies Low‑importance

This article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles

Low This article has been rated as Low-importance on the project's importance scale.

WikiProject Companies To-do:

Here are some tasks awaiting attention:

Article requests : Wikipedia:Requested articles/Business and economics/Companies
Assess : Category:Unassessed company articles
Copyedit : Category:Company articles needing attention
Infobox : Category:Company articles needing infoboxes
Maintain : Portal:Companies
Stubs : Help expand stub articles located at Category:Company stubs
Other :
- Tag company articles with the {{portal|Companies}} template
- Tag company talk pages with the {{WikiProject Companies}} project banner
- Answer requests for comments

The article refers to Verastem as a "direct competitor" of Oncomed. Is this truly the case? It is common practice to improve efficacy by giving multiple drugs in combination, especially if neither has significant side effects. (IE are Oncomed and Verastem complementary, like a doctor and a nurse, or truly adversarial?) Note that Oncomed founder Max Wicha is on the scientific advisory board of Verastem. 98.155.30.229 (talk) 02:58, 30 May 2015 (UTC)Reply

Add topic